phase iii results of prospect study for metastatic, castration-resistant prostate cancer
Published 6 years ago • 133 plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
6:24
phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
-
23:03
metastatic castration resistant prostate cancer: updates from asco 2019
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
19:51
metastatic prostate cancer - interpreting negative trial results
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
5:59
lupsma vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
11:35
nubeqa - a treatment for non-metastatic castration-resistant prostate cancer
-
1:33
fih study of arv-110 in metastatic castrate-resistant prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
18:54
asco 2018: latest developments in non-metastatic & metastatic castration-resistant prostate cancer
-
1:30
rationale for phase iii prospect trial in prostate cancer
-
8:51
esmo 2020 expert video report on precision medicine in prostate cancer
-
14:30
expert video viewpoints on castration-resistant prostate cancer - section 3
-
1:34
dr. chi on the titan trial results in metastatic castration-sensitive prostate cancer
-
4:06
combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer
-
15:06
comparing real world evidence to phase iii data on apalutamide for nmcrpc